Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04613557 · ClinicalTrials.gov registry record · Phase 1
Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 study of Relapse/Refractory Multiple Myeloma, sponsored by Celyad Oncology.
- Active
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 5
- Study locations
NCT04613557 is a Phase 1 study of Relapse/Refractory Multiple Myeloma that is active but no longer recruiting, run by Celyad Oncology. The registered enrollment target is 18 participants. The trial reports 5 study locations across 3 states.
The verdict
NCT04613557, a Phase 1 study of Relapse/Refractory Multiple Myeloma, is active but no longer recruiting, sponsored by Celyad Oncology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of the IMMUNICY-1 study is to assess the safety, activity and cell kinetics of CYAD-211 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen with fludarabine and/or cyclophosphamide
Conditions Studied
Interventions
- DRUG Fludara
- BIOLOGICAL CYAD-211
- DRUG Endoxan
Study Locations (5)
Other
- Universitair Ziekenhuis Antwerpen - Antwerp
- Institut Jules Bordet - Brussels
- AZ DELTA - Roeselare
Florida
- H. Lee Moffitt Cancer Center - Tampa
New York
- Nyu Langone Hospitals - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-11-16 |
| Est. Completion | 2037-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04613557
The ClinicalTrials.gov registry entry for NCT04613557 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celyad Oncology, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapse/Refractory Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Fludara is the first listed.
NCT04613557 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Other, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT04613557 about?
NCT04613557 is a clinical study titled "Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma". The purpose of the IMMUNICY-1 study is to assess the safety, activity and cell kinetics of CYAD-211 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen with fludarabine and/or cyclophosphamide
What is the current status of trial NCT04613557?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2020-11-16. Estimated completion is 2037-02.
What conditions does trial NCT04613557 study?
This clinical trial studies the following conditions: Relapse/Refractory Multiple Myeloma.
What interventions are being tested in trial NCT04613557?
The interventions under investigation include: Fludara (DRUG), CYAD-211 (BIOLOGICAL), Endoxan (DRUG).
Who is sponsoring clinical trial NCT04613557?
This trial is sponsored by Celyad Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04613557 being conducted?
This trial has 5 study locations across Florida, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.